(Q37242614)

19 August 2017

1 reference

title

Pharmacogenetics of oral anticoagulants: a basis for dose individualization (English)

1 reference

19 August 2017

1 reference

1 reference

Simone Stehle

1

1 reference

19 August 2017

Julia Kirchheiner

series ordinal

2

1 reference

19 August 2017

Andreas Lazar

series ordinal

3

1 reference

19 August 2017

Uwe Fuhr

series ordinal

4

1 reference

19 August 2017

publication date

1 January 2008

1 reference

Clinical Pharmacokinetics

19 August 2017

published in

1 reference

19 August 2017

volume

47

1 reference

19 August 2017

issue

9

1 reference

19 August 2017

page(s)

565-594

1 reference

Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions

19 August 2017

cites work

1 reference

12 December 2020

Lovastatin. Warfarin interaction

1 reference

12 December 2020

Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe

1 reference

12 December 2020

Medicine: K is for koagulation.

1 reference

12 December 2020

Biotransformation of tirilazad in human: 1. Cytochrome P450 3A-mediated hydroxylation of tirilazad mesylate in human liver microsomes.

1 reference

12 December 2020

Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose

1 reference

12 December 2020

Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.

1 reference

12 December 2020

Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy

1 reference

12 December 2020

Plasma half-lives, plasma metabolites and anticoagulant efficacies of the enantiomers of warfarin in man

1 reference

12 December 2020

Mass spectral analysis in the identification of human metabolites of warfarin

1 reference

12 December 2020

Genomic sequence and transcription start site for the human gamma-glutamyl carboxylase

1 reference

12 December 2020

Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients

1 reference

12 December 2020

4-Hydroxycoumarin oral anticoagulants: pharmacokinetics-response relationship

1 reference

12 December 2020

A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy.

1 reference

12 December 2020

Warfarin as a probe of cytochromes P-450 function

1 reference

12 December 2020

Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention

1 reference

12 December 2020

Oral anticoagulation with vitamin K antagonists

1 reference

12 December 2020

Lack of effect of cimetidine on pharmacodynamics and kinetics of single oral doses of R- and S-acenocoumarol

1 reference

12 December 2020

Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range

1 reference

12 December 2020

Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect

1 reference

12 December 2020

Determination of the plasma protein binding of the coumarin anticoagulants phenprocoumon and its metabolites, warfarin and acenocoumarol, by ultrafiltration and high-performance liquid chromatography

1 reference

12 December 2020

Hyperforin in St. John's wort drug interactions

1 reference

12 December 2020

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

1 reference

12 December 2020

Analysis of CYP2C9*5 in Caucasian, Oriental and black-African populations

1 reference

12 December 2020

VKORCI haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation

1 reference

12 December 2020

The in vitro ketone reduction of warfarin and analogues. Substrate stereoselectivity, product stereoselectivity and species differences

1 reference

12 December 2020

Factors affecting the maintenance dose of warfarin

1 reference

12 December 2020

Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo

1 reference

12 December 2020

Mechanism of warfarin potentiation by amiodarone: dose--and concentration--dependent inhibition of warfarin elimination.

1 reference

12 December 2020

Several-fold increase in risk of overanticoagulation by CYP2C9 mutations

1 reference

12 December 2020

VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.

1 reference

12 December 2020

Determination of bleeding risk using genetic markers in patients taking phenprocoumon

1 reference

12 December 2020

Transport of vitamin K to bone in humans

1 reference

12 December 2020

The mechanism of action of oral anticoagulants and its consequences for the practice of oral anticoagulation

1 reference

12 December 2020

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

1 reference

12 December 2020

Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patients

1 reference

12 December 2020

Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin

1 reference

12 December 2020

Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.

1 reference

12 December 2020

Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol

1 reference

12 December 2020

Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation

1 reference

12 December 2020

A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance

1 reference

12 December 2020

Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9

1 reference

12 December 2020

VKORC1 and CYP2C9 Genotypes and Phenprocoumon Anticoagulation Status: Interaction Between both Genotypes Affects Dose Requirement

1 reference

12 December 2020

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans

1 reference

12 December 2020

CYP2C9*3 allelic variant and bleeding complications

1 reference

12 December 2020

Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records

1 reference

12 December 2020

Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.

1 reference

12 December 2020

CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.

1 reference

12 December 2020

Genetic modulation of oral anticoagulation with warfarin

1 reference

12 December 2020

Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics

1 reference

12 December 2020

Comparison of the bioavailabilities and anticoagulant activities of two warfarin formulations

1 reference

12 December 2020

Biotransformation of phenprocoumon in the rat

1 reference

12 December 2020

Warfarin metabolism in man: identification of metabolites in urine

1 reference

12 December 2020

Major bleeding caused by warfarin in a genetically susceptible patient

1 reference

12 December 2020

Warfarin analog inhibition of human CYP2C9-catalyzed S-warfarin 7-hydroxylation

1 reference

12 December 2020

The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis.

1 reference

12 December 2020

Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes

1 reference

12 December 2020

Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin

1 reference

12 December 2020

Interindividual variability in sensitivity to warfarin--Nature or nurture?

1 reference

12 December 2020

Genetic-based dosing in orthopedic patients beginning warfarin therapy.

1 reference

12 December 2020

Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.

1 reference

12 December 2020

Comparison of the rat liver microsomal metabolism of the enantiomers of warfarin and 4′-nitrowarfarin (Acenocoumarol)

1 reference

12 December 2020

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

1 reference

12 December 2020

Microsomal vitamin K-dependent carboxylase

1 reference

12 December 2020

Antithrombotic therapy in deep vein thrombosis and pulmonary embolism

1 reference

12 December 2020

Analysis of phenprocoumon and its hydroxylated and conjugated metabolites in human urine by high-performance liquid chromatography after solid-phase extraction

1 reference

12 December 2020

A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk

1 reference

12 December 2020

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

1 reference

12 December 2020

Pharmacogenomics: translating functional genomics into rational therapeutics

1 reference

12 December 2020

Warfarin dose related to apolipoprotein E (APOE) genotype

1 reference

12 December 2020

Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population

1 reference

12 December 2020

Genetic association between sensitivity to warfarin and expression of CYP2C9*3

1 reference

12 December 2020

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range

1 reference

12 December 2020

Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes

1 reference

12 December 2020

CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy

1 reference

12 December 2020

Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin

1 reference

12 December 2020

Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers

1 reference

12 December 2020

The effect of sulfinpyrazone on the disposition of pseudoracemic phenprocoumon in humans

1 reference

12 December 2020

Factors influencing warfarin dose requirements in African-Americans

1 reference

12 December 2020

The roles of vitamins D and K in bone health and osteoporosis prevention

1 reference

12 December 2020

Obesity is associated with a slower response to initial phenprocoumon therapy whereas CYP2C9 genotypes are not

1 reference

12 December 2020

Warfarin Response and Vitamin K Epoxide Reductase Complex 1 in African Americans and Caucasians

1 reference

12 December 2020

Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status

1 reference

12 December 2020

VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation.

1 reference

12 December 2020

APOE genotype makes a small contribution to warfarin dose requirements.

1 reference

12 December 2020

The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon

1 reference

12 December 2020

A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.

1 reference

12 December 2020

The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement

1 reference

12 December 2020

Antithrombotic therapy in atrial fibrillation

1 reference

12 December 2020

Metabolic fate of phenprocoumon in humans

1 reference

12 December 2020

Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.

1 reference

12 December 2020

Stereospecific pharmacokinetic characterisation of phenprocoumon metabolites, and mass-spectrometric identification of two novel metabolites in human plasma and liver microsomes

1 reference

12 December 2020

Patients with an ApoE epsilon4 allele require lower doses of coumarin anticoagulants

1 reference

12 December 2020

Human hepatic microsomal epoxide hydrolase: comparative analysis of polymorphic expression

1 reference

12 December 2020

Biliary excretion of phenprocoumon and metabolites

1 reference

12 December 2020

Clinical Pharmacokinetics of Oral Anticoagulants

1 reference

12 December 2020

Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients

1 reference

12 December 2020

Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose

1 reference

12 December 2020

Assembly of the warfarin-sensitive vitamin K 2,3-epoxide reductase enzyme complex in the endoplasmic reticulum membrane

1 reference

12 December 2020

Warfarin resistance is associated with a protein component of the vitamin K 2,3-epoxide reductase enzyme complex in rat liver.

1 reference

12 December 2020

Epoxide hydrolase--polymorphism and role in toxicology

1 reference

12 December 2020

Absorption of warfarin from the stomach and small intestine.

1 reference

12 December 2020

The human glutathione transferase alpha locus: genomic organization of the gene cluster and functional characterization of the genetic polymorphism in the hGSTA1 promoter

1 reference

12 December 2020

Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9.

1 reference

12 December 2020

Pharmacokinetics of phenprocoumon in man investigated using a gas chromatographic method of drug analysis

1 reference

12 December 2020

Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3.

1 reference

12 December 2020

The warfarin-sulfinpyrazone interaction: stereochemical considerations

1 reference

12 December 2020

Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin

1 reference

12 December 2020

Vitamin K intake and sensitivity to warfarin in patients consuming regular diets

1 reference

12 December 2020

Comparative plasma disposition and anticoagulant activities of racemic phenprocoumon and its metabolites in rats

1 reference

12 December 2020

Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype

1 reference

12 December 2020

Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1.

1 reference

12 December 2020

Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms.

1 reference

12 December 2020

Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose

1 reference

12 December 2020

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

1 reference

12 December 2020

The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon

1 reference

12 December 2020

Intrasubject variation of warfarin binding to protein in serum of patients with cardiovascular disease

1 reference

12 December 2020

Cytochrome P450 polymorphisms are associated with reduced warfarin dose

1 reference

12 December 2020

Adverse reactions to anticoagulants and to antiplatelet drugs recorded by the German spontaneous reporting system

1 reference

12 December 2020

Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin

1 reference

12 December 2020

Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model.

1 reference

12 December 2020

Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.

1 reference

12 December 2020

Pharmacogenetics of warfarin: current status and future challenges

1 reference

12 December 2020

Interactions of warfarin with drugs and food

1 reference

12 December 2020

CYP2C9 allelic variants: ethnic distribution and functional significance

1 reference

12 December 2020

Clinically important drug interactions with anticoagulants. An update

1 reference

12 December 2020

Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions

1 reference

12 December 2020

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

1 reference

12 December 2020

Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes.

1 reference

12 December 2020

Association of congenital deficiency of multiple vitamin K-dependent coagulation factors and the phenotype of the warfarin embryopathy: clues to the mechanism of teratogenicity of coumarin derivatives

1 reference

12 December 2020

Human P450 metabolism of warfarin

1 reference

12 December 2020

CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences

1 reference

12 December 2020

Genetic mechanisms for hypersensitivity and resistance to the anticoagulant Warfarin

1 reference

12 December 2020

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.

1 reference

12 December 2020

Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes

1 reference

12 December 2020

Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.

1 reference

12 December 2020

Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.

1 reference

12 December 2020

The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase

1 reference

12 December 2020

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation

1 reference

12 December 2020

Chromosomal localization of the gamma-glutamyl carboxylase gene at 2p12.

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man

1 reference

12 December 2020

Biotransformation and pharmacokinetics of acenocoumarol (Sintrom�) in man

1 reference

12 December 2020

Phylloquinone transport and its influence on gamma-carboxyglutamate residues of osteocalcin in patients on maintenance hemodialysis.

1 reference

12 December 2020

Association of warfarin dose with genes involved in its action and metabolism

1 reference

12 December 2020

Retrospective analyses of acenocoumarol doses and bleeding complications in patients with wild type or variant cytochrome P450 CYP2C9 alleles

1 reference

12 December 2020

Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves

1 reference

12 December 2020

Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro

1 reference

12 December 2020

Compound heterozygous mutations in the gamma-glutamyl carboxylase gene cause combined deficiency of all vitamin K-dependent blood coagulation factors

1 reference

12 December 2020

Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone

1 reference

12 December 2020

Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants

1 reference

12 December 2020

Isolation of the human gamma-carboxylase and a gamma-carboxylase-associated protein from factor IX-expressing mammalian cells.

1 reference

12 December 2020

Cytochrome P450 2C9 polymorphism and acenocoumarol therapy

1 reference

12 December 2020

Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.

1 reference

12 December 2020

R- and S-Warfarin inhibition of vitamin K and vitamin K 2,3-epoxide reductase activities in the rat

1 reference

12 December 2020

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

1 reference

12 December 2020

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range

1 reference

12 December 2020

CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis

1 reference

12 December 2020

In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin*

1 reference

12 December 2020

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

1 reference

12 December 2020

Pharmacogenetics of warfarin elimination and its clinical implications

1 reference

12 December 2020

The enantiomers of phenprocoumon: pharmacodynamic and pharmacokinetic studies

1 reference

12 December 2020

10.2165/00003088-200847090-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

19 August 2017

1034126284

0 references

1 reference